Läs upp

Cookies

Den här webbplatsen använder så kallade cookies. Cookies är små textfiler som lagras i din dator och sparar information om olika val som du gjort på en webbsida – t ex språk, version och statistik – för att du inte ska behöva göra dessa val en gång till. Tekniken är etablerad sedan många år tillbaka och används idag på väldigt många webbplatser på Internet.

Du kan när som helst ändra cookieinställningarna för denna webbplats.

FASS logotyp
Receptbelagd

Peka på symbolerna och beteckningarna till vänster för en förklaring.

Kontakt och länkar

Sök apotek med läkemedlet i lager

Sök lagerstatus

Hycamtin

MiljöinformationReceptstatusFörmånsstatus
Novartis

Kapsel, hård 0,25 mg
(Kapslarna är ogenomskinliga, vita till gulvita och märkta med HYCAMTIN och 0,25 mg.)

Andra antineoplastiska medel

Aktiv substans:
ATC-kod: L01XX17
Utbytbarhet: Ej utbytbar
Läkemedel från Novartis omfattas av Läkemedelsförsäkringen.
  • Vad är miljöinformation?

Miljöpåverkan (Läs mer om miljöpåverkan)

Topotekan

Miljörisk: Risk för miljöpåverkan av topotekan kan inte uteslutas då det inte finns tillräckliga ekotoxikologiska data.
Nedbrytning: Topotekan är potentiellt persistent.
Bioackumulering: Topotekan har låg potential att bioackumuleras.


Läs mer

Detaljerad miljöinformation

Environmental Risk Classification


Predicted Environmental Concentration (PEC)

PEC is calculated according to the following formula:

PEC (μg/L) = (A*109*(100-R)/(365*P*V*D*100) = 1.5*10-6*A(100-R) = 1.5*10-6 * 0.0083 * 100

PEC = 0.000001245 μg/L

Where:

A = 0.0083 kg (total sold amount API in Sweden year 2015, data from IMS Health).

R = 0% removal rate (conservatively, it has been assumed there is no loss by adsorption to sludge particles, by volatilization, hydrolysis or biodegradation)

P = number of inhabitants in Sweden = 9 *106

V (L/day) = volume of wastewater per capita and day = 200 (ECHA default) (Reference 1)

D = factor for dilution of waste water by surface water flow = 10 (ECHA default) (Reference 1)


Predicted No Effect Concentration (PNEC)

Ecotoxicological studies

Green Algae:

No data (not possible due to rapid photolysis)


Water flea (Daphnia magna):

Acute toxicity

EC50 48 h (immobility) = 61,800 μg/L (OECD 202) (Reference 3)


Water flea:

Chronic toxicity

No data


Rainbow Trout (Oncorhyncus mykiss):

Acute toxicity

LC50 96 h (immobility) = 45,700 μg/L (OECD 203) (Reference 3)


Fathead minnow:

Chronic toxicity

No data


Other ecotoxicity data:

Microorganisms in activated sludge

EC50 3 hours (Inhibition) =102,000 μg/L (OECD 209) (Reference 3)


PNEC cannot be calculated because data is not available for all three (algae, crustacean and fish) of the short-term toxicity endpoints.


Environmental risk classification (PEC/PNEC ratio)

Risk of environmental impact of topotecan cannot be excluded, since there is not sufficient ecotoxicity data available.


Degradation

Biotic degradation

Ready degradability:

0% degradation in 28 days (OECD 301B) (Reference 3)


Inherent degradability:

No data


Abiotic degradation

Hydrolysis:

Half-life, pH 7 = 35 years (TAD 3.09) (Reference 3)


Photolysis:

Half-life, pH 7 = 2.51m (TAD 3.10) (Reference 3)


Justification of chosen degradation phrase:

Topotecan is not readily biodegradable. The phrase “Topotecan is potentially persistent” is thus chosen.


Bioaccumulation

Partitioning coefficient:

Log Dow = 0.80 at pH7. (TAD 3.02) (Reference 4)


Justification of chosen bioaccumulation phrase:

Since log Dow < 4, the substance has low potential for bioaccumulation.


Excretion (metabolism)

Metabolism accounts for < 10% of the elimination of topotecan. An N-desmethyl metabolite, which was shown to have similar or less activity than the parent in a cell-based assay, was found in urine, plasma, and faeces. The mean metabolite:parent AUC ratio was less than 10 % for both total topotecan and topotecan lactone. An O-glucuronidation metabolite of topotecan and N-desmethyl topotecan has been identified in the urine.

Overall recovery of medicinal product-related material following five daily doses of topotecan was 71 to 76 % of the administered IV dose. Approximately 51 % was excreted as total topotecan and 3 % was excreted as N-desmethyl topotecan in the urine. Faecal elimination of total topotecan accounted for 18 % while faecal elimination of N-desmethyl topotecan was 1.7 %. Overall, the N-desmethyl metabolite contributed a mean of less than 7% (range 4-9 %) of the total medicinal product related material accounted for in the urine and faeces. The topotecan-O-glucuronide and N-desmethyl topotecan-O-glucuronide in the urine were less than 2.0 %. (Reference 2)


PBT/vPvB assessment

Topotecan does not fulfil the criteria for PBT and/or vBvP.


All three properties, i.e. ‘P’, ‘B’ and ‘T’ are required in order to classify a compound as PBT (Reference 1). Topotecan does not fulfil the criteria for PBT and/or vBvP based on a log Dow < 4.


References


1. ECHA, European Chemicals Agency. 2008 Guidance on information requirements and chemical safety assessment.


2. Pharmacokinetic properties: Metabolism and Elimination. Summary of Product Characteristics Hycamtin (Topotecan) Solution for Infusion. GlaxoSmithKline, November 2010.


3. Ziegenfuss P. Hycamtin, SK&F 104864, topotecan, environmental risk assessment, ERA, Phase I, environmental fate, environmental effects. Report No. ERL 9809. SmithKline Beecham Environmental Research Laboratory, June 1998.


4. ACD /LogD. June 2012. Advanced Chemistry Development, Inc.

Välj läkemedelstext
Hitta direkt i texten
Av